AtriCure, Inc. (NASDAQ:ATRC) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET
Company Participants
Marissa Bych - Investor Relations
Michael Carrel - President and Chief Executive Officer
Angela Wirick - Chief Financial Officer
Conference Call Participants
Lilia Lozada - JPMorgan
John Newman - Canaccord Genuity
John McAulay - Stifel Financial Corp.
Sam Eiber - BTIG
Danielle Antalffy - UBS
Daniel Stauder - Citizens JMP
Suraj Kalia - Oppenheimer & Co.
Joseph Conway - Needham & Company
Operator
Good afternoon, And welcome to AtriCure's Second Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes. [Operator Instructions]
I would now like to turn the call over to Marissa Bych, from the Gilmartin Group for a few introductory comments.
Marissa Bych
Great. Thank you, operator. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call (513) 644 4484 to have one e-mailed to you.
Before we begin today, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings. These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure franchises and growth initiatives, future product approvals, clearances, competition, reimbursement and clinical trial outcomes. AtriCure's results may differ materially from those projected.
AtriCure undertakes no obligation to publicly update any forward-looking statements. Additionally, we refer to non-GAAP financial measures, specifically revenue reported on a constant currency basis, adjusted EBITDA and adjusted loss per share. A reconciliation of these non-GAAP financial measures with the most directly comparable GAAP measures is included in our press release, which is available on our website.
And with that, I would like to turn the call over to Mike Carrel, President and Chief Executive Officer of AtriCure.
Michael Carrel
Great. Good afternoon, everyone, and thank you for joining us. I am pleased to highlight another strong quarter at AtriCure driven by our unwavering commitment to treatment of patients with atrial fibrillation and postoperative pain. We achieved total revenue of $116 million, reflecting over 15% growth, driven by increasing demand across our portfolio of technologies.
Our results were underscored by accelerated growth in several areas of business, including US pain management, US open appendage management and across our international franchises. We also continue our path towards sustained profitability, generating nearly $8 million in positive adjusted EBITDA for the quarter. Additionally, we reached an exciting milestone with positive cash flow generation of over $8 million this quarter, and we plan to generate positive cash flow for the remainder of the year.